Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
It will be marketed under the brand name Molunamax
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
Jardiance is the first SGLT2-inhibitor therapy to prove reduction in risk of cardiovascular death in people with type-II diabetes and established cardiovascular disease
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Subscribe To Our Newsletter & Stay Updated
